Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Key Takeaways
Introduction
Alzheimer’s disease affects an estimated 55 million people worldwide. It is, for most of those affected, untreatable in any meaningful sense — a slow, irreversible deterioration against which medicine has made frustratingly little progress. The drugs approved to date modify symptoms rather than disease course, and the pipeline for disease-modifying therapies has been littered with high-profile failures.
Against that backdrop, the emerging evidence linking periodontal disease to Alzheimer’s has attracted considerable attention — not only from researchers but from neurologists, geriatricians, and increasingly from dental professionals who recognise that their patients may be managing cognitive risk as well as gingival health. A cluster of significant reviews and studies published through 2025 have substantially strengthened this evidence base. What follows is a synthesis of where the science currently stands.
The Core Finding: P. gingivalis in the Brain
The most striking single finding in this field — and the one that has done most to elevate the conversation beyond the epidemiological — is the detection of Porphyromonas gingivalis in the brain tissue of individuals with Alzheimer’s disease.
Researchers have found that P. gingivalis — the primary pathogen responsible for periodontal disease — was present in the brains of Alzheimer’s patients. The bacteria’s toxic proteases, called gingipains, have been found co-localised with tau tangles and amyloid plaques in affected brain tissue. This is not merely a statistical association between two common conditions — it is a biological fingerprint of a specific oral pathogen in the central nervous system, identified at the very sites of Alzheimer’s pathology.
In murine models, oral infection with P. gingivalis resulted in brain colonisation and increased amyloid-β production. Moreover, P. gingivalis DNA and gingipains have been detected in the hippocampus of Alzheimer’s patients, suggesting a potential mechanistic pathway between oral infection and neurodegeneration.
University Hospitals neurologist Dr Mohamed Elkasaby summarises the concern plainly: “Poor oral hygiene and chronic gum infections pose potential risk for developing neurodegenerative disorders. This bacteria has been detected in the brains of individuals with Alzheimer’s disease. It is thought to contribute to the pathology of the disease.”
The Epidemiological Weight: 52 Studies and Counting
A September 2025 scoping review published in Frontiers in Aging Neuroscience conducted a comprehensive sweep of the literature, screening 1,369 records and ultimately including 52 studies — 25 clinical studies examining the association directly, 24 investigating underlying mechanisms, and 3 animal studies assessing periodontal interventions for Alzheimer’s pathology. The overall conclusion was clear: evidence suggests periodontal disease increases the risk of Alzheimer’s and accelerates cognitive decline, with potential mechanisms including amyloid-β and tau protein aggregation, neuroinflammation triggered by P. gingivalis infection, and gut-brain axis dysregulation.
A separate PRISMA-guided systematic review published in June 2025 in Applied Sciences, which screened 1,244 articles and included 19 that met rigorous inclusion criteria, found that periodontal pathogens, such as P. gingivalis, promote neuroinflammation, amyloid-β aggregation, and brain atrophy. Elevated inflammatory markers and oral dysbiosis correlated with increased Alzheimer’s risk. Periodontal treatment demonstrated benefits in reducing systemic inflammation and stabilising cognitive decline.
The tooth loss data is particularly sobering. Research suggests that the risk of dementia rises by 1.1% and the risk of cognitive impairment by 1.4% for every tooth lost. Given that most tooth loss in adults is attributable to periodontitis, this finding places gum disease squarely in the causal chain.
The Mechanisms: How the Mouth Reaches the Brain
Three pathways are now considered central to the periodontal-Alzheimer’s relationship.
Direct microbial invasion. The inflamed periodontal pocket is an ulcerated surface — a port of entry for oral bacteria into the systemic circulation. Oral bacteria and inflammatory molecules from gum disease can travel through the blood and penetrate the blood-brain barrier. Once in the brain, P. gingivalis activates microglia — the brain’s immune cells — and drives a neuroinflammatory cascade that shares key features with Alzheimer’s pathology.
The inflammatory cascade. Chronic periodontal disease elevates pro-inflammatory cytokines including IL-1β, IL-6, and TNF-α, which traverse the blood-brain barrier, activate microglia, and drive neuroinflammation — a hallmark of Alzheimer’s pathology. This is the same inflammatory system that has been implicated in cardiovascular disease, diabetes, and a range of other systemic conditions — reinforcing the view that periodontitis is a systemic disease with a local presentation.
Gut-brain axis dysregulation. A more recently explored pathway involves the oral-gut-brain axis. Periodontal pathogens swallowed in saliva can alter the gut microbiome, and the gut microbiome is increasingly understood to modulate neuroinflammation and cognitive function through multiple mechanisms. This is an area of active research with significant implications for future therapeutic strategies.
The Bidirectional Relationship
One of the most clinically important aspects of this evidence is that the relationship between periodontitis and Alzheimer’s appears to run in both directions. Cognitive decline in Alzheimer’s reduces a patient’s ability to perform adequate oral hygiene, increasing periodontal inflammation, while chronic periodontal infection may in turn contribute to neuroinflammation and accelerate cognitive deterioration — creating a cycle of mutual exacerbation.
This has direct implications for how we manage older patients with cognitive impairment in the dental setting. The patient who struggles to maintain oral hygiene because of early Alzheimer’s is not simply a difficult case to manage — they are a patient in whom poor periodontal health may be actively contributing to their neurological decline. This bidirectional framing makes the dental professional’s role in the care of cognitively impaired older adults considerably more significant than it has traditionally been recognised.
Can Treating Gum Disease Protect the Brain?
This is the question the research community is now working hard to answer. The observational evidence is encouraging. Studies have reported a lower risk of Alzheimer’s among individuals who received long-term periodontal care. Gingipain inhibitors have been shown in preclinical studies to reduce amyloid-β production, dampen neuroinflammation, and protect hippocampal neurons.
Clinically, periodontal treatment has been shown to reduce systemic inflammation, stabilise cognition, and mitigate brain atrophy — underscoring periodontitis as a potentially modifiable Alzheimer’s risk factor.
A randomised controlled trial currently registered on ClinicalTrials.gov is directly testing whether periodontal therapy in patients with mild to moderate Alzheimer’s dementia can produce measurable improvements on the Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog 11) over a 52-week treatment period — comparing active periodontal therapy against placebo across approximately 190 patients aged 55 to 80, with a primary aim of demonstrating at least a 2.5-point difference on the ADAS-Cog 11 at the end of treatment. The results of this trial will be pivotal.
For now, the most intellectually honest summary is this: the association is strong, the mechanisms are biologically plausible and in some cases directly demonstrated, and the intervention data is promising but not yet definitive. Causality has not been formally established through the gold standard of large-scale randomised controlled trials.
What This Means for Practice
The clinical implications are actionable even before causality is fully established.
For dental practitioners, the case for treating periodontitis aggressively in older patients — particularly those over 65 or with family histories of dementia — is already compelling on systemic grounds. The accumulating Alzheimer’s data adds further weight to that argument. Routine periodontal screening in older patients should be understood not only as dental care but as a component of dementia risk reduction.
For the profession more broadly, this evidence base strengthens the case for closer integration between dental and medical care. A neurologist or geriatrician managing a patient with early cognitive decline should, ideally, be asking about their oral health — and referring to a periodontist if there are signs of active disease. That referral pathway does not yet exist in most healthcare systems, but the evidence is now sufficient to begin building it.
And for patients, the message is not one of alarm but of empowerment. Gum disease is treatable, and managing it effectively may help reduce the risk of systemic conditions, including Alzheimer’s. Taking care of your gums is about more than protecting your teeth — it is a critical component of protecting your overall health, including brain function.
Key Unanswered Questions
The field is moving rapidly but several important questions remain open. Does treating periodontitis in middle age reduce Alzheimer’s incidence decades later? Is the relationship primarily driven by P. gingivalis specifically, or by the broader inflammatory burden of periodontal disease? Which patients are most at risk — and are there genetic factors, such as APOE4 carrier status, that amplify the oral-brain connection? Can gingipain inhibitors be developed into viable therapeutic agents for Alzheimer’s prevention?
Large-scale longitudinal studies and the results of ongoing clinical trials will be essential to answering these questions. But the direction of travel in this research is clear — and for a disease as devastating and as poorly treated as Alzheimer’s, a modifiable, treatable risk factor in the form of periodontitis represents a genuinely significant opportunity.
Sources: Frontiers in Aging Neuroscience, September 2025 (scoping review, 52 studies, n=1,369 screened); Applied Sciences, June 2025 (systematic review, PRISMA, n=1,244 screened); ScienceDirect/Periodontal Medicine Biomarkers, January 2025 (narrative review); PMC/MDPI, June 2025 (comprehensive review); ClinicalTrials.gov NCT05183321 (ongoing RCT); University Hospitals Health System, July 2025.
